Real-World Studies
Enzalutamide Linked to Longer Time to CRPC Than Apalutamide in mCSPC Cohort
Ohtani et alJapanese journal of clinical oncology

In a retrospective, multicenter study evaluating 331 consecutive patients with metastatic castration-sensitive prostate cancer (mCSPC), researchers compared real-world effectiveness, treatment modifications, and safety outcomes between first-line apalutamide (n = 208) and enzalutamide (n = 123). Propensity score matching generated 85 balanced pairs (maximum post-match absolute standardized mean difference of 0.073) to analyze the primary endpoint: time to clinically documented castration-resistant prostate cancer (CRPC), defined by prostate-specific antigen (PSA) and/or radiographic progression in a castrate state.
The primary matching analysis showed that time to clinically documented CRPC was shorter in patients receiving apalutamide compared to enzalutamide (HR 2.13, 95% CI 1.08–4.19; P = .029). These findings were corroborated in sensitivity analyses using stabilized inverse probability of treatment weighting (IPTW) (HR 2.04, 95% CI 1.10–3.75; P = .023) as well as IPTW adjusting for CHAARTED high-volume and LATITUDE high-risk disease burden (HR 2.15, 95% CI 1.13–4.08; P = .020).
Time to achieve a PSA level <0.1 ng/ml was similar between apalutamide and enzalutamide (HR 1.00, 95% CI 0.66–1.51; P = .996), and overall survival was also comparable (HR 1.30, 95% CI 0.54–3.11; P = .557). Regarding tolerability and treatment delivery, apalutamide therapy was associated with higher frequencies of dose reductions, adverse events, and non-progression-related treatment interruptions or discontinuations. The authors noted that while weighted sensitivity analyses supported the primary association, residual confounding and a limited number of events preclude causal claims.
Key Takeaways
- In a propensity score-matched cohort of patients with metastatic castration-sensitive prostate cancer, apalutamide was associated with a shorter time to clinically documented castration-resistant prostate cancer compared to enzalutamide (HR 2.13, 95% CI 1.08–4.19; P = .029), which remained consistent in stabilized IPTW (HR 2.04, 95% CI 1.10–3.75; P = .023) and disease-burden-adjusted IPTW analyses (HR 2.15, 95% CI 1.13–4.08; P = .020).
- Dose reductions, adverse events, and non-progression-related treatment interruptions or discontinuations occurred more frequently with apalutamide, while overall survival (HR 1.30, 95% CI 0.54–3.11; P = .557) and time to reach a PSA level <0.1 ng/ml (HR 1.00, 95% CI 0.66–1.51; P = .996) were similar between the cohorts.
Read the original sourceJapanese journal of clinical oncology
